Though it's still struggling with data integration, Detroit's Henry Ford Health System is standardizing workflows and beginning to measure outcomes.
Precision cancer company Syapse is teaming with Seoul National University Hospital and Asian AWS partner Megazone
Pharmaceutical giant Roche has entered into a collaboration with Syapse to widen access to precision oncology technology and services.
Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.
Through the deal, Sylvester will have access to Syapse's precision medicine platform for cancer care.
The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
The two health systems have also joined the OPeN consortium and plan to share cancer patient data in support of the Cancer Moonshot Initiative.
Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.